New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
08:07 EDTMNKMallinckrodt MNK-155 NDA accepted for review by FDA
Mallinckrodt announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for MNK-155. MNK-155 is an investigational extended-release oral formulation of hydrocodone and acetaminophen studied for the management of moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate. The NDA submission was based on positive efficacy results in a Phase 3 clinical trial, in addition to a series of other clinical trials evaluating pharmacokinetics, safety and abuse liability of MNK-155.
News For MNK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
08:17 EDTMNKMallinckrodt price target raised to $115 from $107 at Buckingham
Subscribe for More Information
September 22, 2014
10:16 EDTMNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
05:49 EDTMNKMallinckrodt reinstated with an Overweight at Barclays
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use